A U.S. Food and Drug Administration panel recently voted 6-4 against approving a drug by Amylyx Pharmaceuticals that many hoped could help those diagnosed with ALS, or Lou Gehrig's disease. ALS is a progressive neurodegenerative disease that attacks nerve cells needed to control muscles throughout the body.
So what now? Many are still hopeful for a breakthrough treatment in drug trials, including Hawaiʻi Public Radio President and General Manager José Fajardo who is living with ALS. Fajardo shared his reaction to the FDA panel's decision, as well as his personal journey with the disease.
This interview aired on The Conversation on April 8, 2022. The Conversation airs weekdays at 11 a.m. on HPR-1.
